Avapritinib

阿伐替尼

Report date: 2024/06/14 16:12:25
NME

Base Information

Drug NameAvapritinib
Drug Alias Name阿泊替尼AyvakitAyvakyt泰吉华Taijihua +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor alpha inhibitorsStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptor alpha
Therapy Area/IndicationsSolid tumoursLung NeoplasmsCentral Nervous System Neoplasms +[14] 
Global Approved IndicationsGastrointestinal Stromal Tumors
Approved Indications in ChinaGastrointestinal Stromal Tumors
Original Approved Country/TerritoryUnited States
Original Approved Date2020/01/09
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBlueprint Medicines Corp
China Registration ClassN/A

Develop Information

Active CompaniesBlueprint Medicines (Netherlands) BvThe University Of Texas MD Anderson Cancer CenterCstone Pharmaceuticals +[5] 
Inactive CompaniesJuniper Pharma Services LtdCstone Pharmaceuticals (Suzhou) Co Ltd
Active IndicationsSolid tumoursLung NeoplasmsCentral Nervous System Neoplasms +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG